Annual General Meeting held
Navamedic ASA: Granted European patent for Sippi® base technology
Navamedic ASA: Notice of Annual General Meeting
Navamedic ASA: Q1 2017 results
Oslo, 10 May 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 78.2 million in the first quarter of 2017 (NOK 60.8 million in Q1 2016), representing a growth of 28.6%, in part due to a widened distribution across new European markets under the partnership with TopRidge Pharma.